Markets
Matinas BioPharma Holdings, Inc. (MTNB)
MTNBAMEXBiotechnology: Pharmaceutical Preparations
$1.25
+0.0100 (+0.81%) today
Regular session, Nov 10, 12:05 PM ET
+0.81% 1D
- Market cap
- $1.22m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.22 to $1.26
- 52-week range
- $0.9662 to $19.95
- Average volume
- 2.29m
- Previous close
- $1.24
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$1.58m | -$1.60m | -$1.94m | -$1.55m |
| Net income | -$1.53m | -$1.91m | -$1.92m | -$1.33m |
News
8 latest- Matinas BioPharma Receives NYSE American Non-Compliance Notice RTTNews · Sep 7, 2026
- Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data RTTNews · Jul 18, 2026
- Matinas BioPharma To Merge With GH Power; Sells LNC Platform And MAT2203 To Azurity Pharmaceuticals RTTNews · Jul 14, 2026
- Matinas BioPharma Receives Additional NYSE Notice Of Non-Compliance; Compliance Plan Accepted RTTNews · Jun 29, 2026
- $MTNB Earnings Preview: Recent $MTNB Insider Trading, Hedge Fund Activity, and MoreQuiver Quantitative · Mar 23, 2025
- Matinas BioPharma Appoints Keith Murphy and Edward Neugeboren to Board of DirectorsQuiver Quantitative · Mar 11, 2025
- Matinas BioPharma Holdings, Inc. Secures $3.3 Million in Financing and Appoints Dr. Robin L. Smith to Board of DirectorsQuiver Quantitative · Feb 13, 2025
- Matinas BioPharma Appoints Evelyn D’An as Independent Director and Audit Committee ChairQuiver Quantitative · Feb 7, 2025
The company
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- Region
- North America
- Website
- matinasbiopharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.